{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T06:11:29Z","timestamp":1779343889753,"version":"3.51.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2001,2,1]],"date-time":"2001-02-01T00:00:00Z","timestamp":980985600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2001,2]]},"DOI":"10.1038\/84683","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T08:47:57Z","timestamp":1027673277000},"page":"228-234","source":"Crossref","is-referenced-by-count":259,"title":["Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR\u2013ABL tyrosine kinase"],"prefix":"10.1038","volume":"7","author":[{"given":"Paolo","family":"Vigneri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Y. J.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2001,2,1]]},"reference":[{"key":"BFnm0201228_CR1","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1056\/NEJM199907153410306","volume":"341","author":"S Faderl","year":"1999","unstructured":"Faderl, S. et al. The biology of chronic myeloid leukemia. N. Engl. J. Med. 341, 164\u2013172 (1999).","journal-title":"N. Engl. J. Med."},{"key":"BFnm0201228_CR2","doi-asserted-by":"publisher","first-page":"207","DOI":"10.7326\/0003-4819-131-3-199908030-00008","volume":"131","author":"S Faderl","year":"1999","unstructured":"Faderl, S., Talpaz, M., Estrov, Z. & Kantarjian, H.M. Chronic myelogenous leukemia: biology and therapy. Ann. Intern. Med. 131, 207\u2013219 (1999).","journal-title":"Ann. Intern. Med."},{"key":"BFnm0201228_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s002770050473","volume":"78","author":"M Warmuth","year":"1999","unstructured":"Warmuth, M., Danhauser-Riedl, S. & Hallek, M. Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies. Ann. Hematol. 78, 49\u201364 (1999).","journal-title":"Ann. Hematol."},{"key":"BFnm0201228_CR4","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1126\/science.2406902","volume":"247","author":"GQ Daley","year":"1990","unstructured":"Daley, G.Q., Van Etten, R.A. & Baltimore, D. Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome. Science 247, 824\u2013830 (1990).","journal-title":"Science"},{"key":"BFnm0201228_CR5","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/blood.V92.10.3780","volume":"92","author":"WS Pear","year":"1998","unstructured":"Pear, W.S. et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr\/abl-transduced bone marrow. Blood 92, 3780\u20133792 (1998).","journal-title":"Blood"},{"key":"BFnm0201228_CR6","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood.V92.10.3829","volume":"92","author":"X Zhang","year":"1998","unstructured":"Zhang, X. & Ren, R. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood 92, 3829\u20133840 (1998).","journal-title":"Blood"},{"key":"BFnm0201228_CR7","doi-asserted-by":"crossref","unstructured":"Wang, J.Y.J. in Integrative signaling through Abl: a tyrosine kinase with nuclear and cytoplasmic functions, 303\u2013324 (Humana Press, Totowa, New Jersey, 2000).","DOI":"10.1385\/1-59259-218-X:303"},{"key":"BFnm0201228_CR8","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1128\/MCB.12.4.1864","volume":"12","author":"GQ Daley","year":"1992","unstructured":"Daley, G.Q., Van Etten, R.A., Jackson, P.K., Bernards, A. & Baltimore, D. Nonmyristoylated Abl proteins transform a factor-dependent hematopoietic cell line. Mol. Cell. Biol. 12, 1864\u20131871 (1992).","journal-title":"Mol. Cell. Biol."},{"key":"BFnm0201228_CR9","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1128\/MCB.15.3.1286","volume":"15","author":"MW Renshaw","year":"1995","unstructured":"Renshaw, M.W., McWhirter, J.R. & Wang, J.Y. The human leukemia oncogene bcr-abl abrogates the anchorage requirement but not the growth factor requirement for proliferation. Mol. Cell. Biol. 15, 1286\u20131293. (1995).","journal-title":"Mol. Cell. Biol."},{"key":"BFnm0201228_CR10","doi-asserted-by":"publisher","first-page":"6151","DOI":"10.1093\/emboj\/16.20.6151","volume":"16","author":"T Skorski","year":"1997","unstructured":"Skorski, T. et al. Transformation of hematopoietic cells by BCR\/ABL requires activation of a PI-3k\/Akt-dependent pathway. EMBO J. 16, 6151\u20136161 (1997).","journal-title":"EMBO J."},{"key":"BFnm0201228_CR11","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1182\/blood.V91.5.1700","volume":"91","author":"GP Amarante-Mendes","year":"1998","unstructured":"Amarante-Mendes, G.P. et al. Bcr\u2013Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood 91, 1700\u20131705 (1998).","journal-title":"Blood"},{"key":"BFnm0201228_CR12","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/j.1460-2075.1993.tb05797.x","volume":"12","author":"JR McWhirter","year":"1993","unstructured":"McWhirter, J.R. & Wang, J.Y. An actin-binding function contributes to transformation by the Bcr\u2013Abl oncoprotein of Philadelphia chromosome+ human leukemias. EMBO J. 12, 1533\u20131546 (1993).","journal-title":"EMBO J."},{"key":"BFnm0201228_CR13","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/j.1460-2075.1996.tb00503.x","volume":"15","author":"ST Wen","year":"1996","unstructured":"Wen, S.T., Jackson, P.K. & Van Etten, R.A. The cytostatic function of Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene products. EMBO J. 15, 1583\u20131595 (1996).","journal-title":"EMBO J."},{"key":"BFnm0201228_CR14","doi-asserted-by":"publisher","first-page":"7457","DOI":"10.1073\/pnas.95.13.7457","volume":"95","author":"S Taagepera","year":"1998","unstructured":"Taagepera, S. et al. Nuclear-cytoplasmic shuttling of ABL tyrosine kinase. Proc. Natl. Acad. Sci. USA 95, 7457\u20137462 (1998).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm0201228_CR15","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/S0092-8674(00)80371-2","volume":"90","author":"M Fornerod","year":"1997","unstructured":"Fornerod, M., Ohno, M., Yoshida, M. & Mattaj, I.W. CRM1 is an export receptor for leucine-rich nuclear export signals. Cell 90, 1051\u20131060 (1997).","journal-title":"Cell"},{"key":"BFnm0201228_CR16","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/36894","volume":"390","author":"M Fukuda","year":"1997","unstructured":"Fukuda, M. et al. CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature 390, 308\u2013311 (1997).","journal-title":"Nature"},{"key":"BFnm0201228_CR17","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/387516a0","volume":"387","author":"R Baskaran","year":"1997","unstructured":"Baskaran, R. et al. Ataxia telangiectasia mutant protein activates Abl tyrosine kinase in response to ionizing radiation. Nature 387, 516\u2013519 (1997).","journal-title":"Nature"},{"key":"BFnm0201228_CR18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/38298","volume":"389","author":"CA Jost","year":"1997","unstructured":"Jost, C.A., Marin, M.C. & Kaelin, W.G., Jr. p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature 389, 191\u2013194 (1997); erratum: 399, 817 (1999).","journal-title":"Nature"},{"key":"BFnm0201228_CR19","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/21690","volume":"399","author":"JG Gong","year":"1999","unstructured":"Gong, J.G. et al. The tyrosine kinase Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature. 399, 806\u2013809 (1999).","journal-title":"Nature."},{"key":"BFnm0201228_CR20","doi-asserted-by":"publisher","first-page":"5643","DOI":"10.1038\/sj.onc.1203878","volume":"20","author":"JYJ Wang","year":"2000","unstructured":"Wang, J.Y.J. Regulation of cell death by the Abl tyrosine kinase. Oncogene 20, 5643\u20135650 (2000).","journal-title":"Oncogene"},{"key":"BFnm0201228_CR21","first-page":"100","volume":"56","author":"E Buchdunger","year":"1996","unstructured":"Buchdunger, E. et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56, 100\u2013104 (1996).","journal-title":"Cancer Res."},{"key":"BFnm0201228_CR22","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker, B.J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Med. 2, 561\u2013566 (1996).","journal-title":"Nature Med."},{"key":"BFnm0201228_CR23","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/jnci\/91.2.163","volume":"91","author":"P le Coutre","year":"1999","unstructured":"le Coutre, P. et al. In vivo eradication of human BCR\/ABL-positive leukemia cells with an ABL kinase inhibitor. J. Natl. Cancer Inst. 91, 163\u2013168 (1999).","journal-title":"J. Natl. Cancer Inst."},{"key":"BFnm0201228_CR24","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood.V90.9.3691","volume":"90","author":"MW Deininger","year":"1997","unstructured":"Deininger, M.W., Goldman, J.M., Lydon, N. & Melo, J.V. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of Bcr-Abl-positive cells. Blood 90, 3691\u20133698 (1997).","journal-title":"Blood"},{"key":"BFnm0201228_CR25","first-page":"1661","volume":"4","author":"M Beran","year":"1998","unstructured":"Beran, M. et al. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin. Cancer Res. 4, 1661\u20131672 (1998).","journal-title":"Clin. Cancer Res."},{"key":"BFnm0201228_CR26","doi-asserted-by":"publisher","first-page":"7587","DOI":"10.1128\/MCB.13.12.7587","volume":"13","author":"JR McWhirter","year":"1993","unstructured":"McWhirter, J.R., Galasso, D.L. & Wang, J.Y. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr\u2013Abl oncoproteins. Mol. Cell. Biol. 13, 7587\u20137595 (1993).","journal-title":"Mol. Cell. Biol."},{"key":"BFnm0201228_CR27","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","volume":"289","author":"T Schindler","year":"2000","unstructured":"Schindler, T. et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289, 1938\u20131942 (2000).","journal-title":"Science"},{"key":"BFnm0201228_CR28","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/ijc.2910180405","volume":"18","author":"E Klein","year":"1976","unstructured":"Klein, E. et al. Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia. Int. J. Cancer 18, 421\u2013431 (1976).","journal-title":"Int. J. Cancer"},{"key":"BFnm0201228_CR29","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.1182\/blood.V91.10.3927.3927_3927_3934","volume":"91","author":"KM Klucher","year":"1998","unstructured":"Klucher, K.M., Lopez, D.V. & Daley, G.Q. Secondary mutation maintains the transformed state in BaF3 cells with inducible BCR\/ABL expression. Blood 91, 3927\u20133934 (1998).","journal-title":"Blood"},{"key":"BFnm0201228_CR30","doi-asserted-by":"publisher","first-page":"9112","DOI":"10.1073\/pnas.96.16.9112","volume":"96","author":"N Kudo","year":"1999","unstructured":"Kudo, N. et al. Leptomycin B inactivates CRM1\/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc. Natl. Acad. Sci. USA 96, 9112\u20139117 (1999).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm0201228_CR31","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1084\/jem.189.9.1399","volume":"189","author":"S Li","year":"1999","unstructured":"Li, S., Ilaria, R.L. Jr, Million, R.P., Daley, G.Q. & Van Etten, R.A. The P190, P210 and P230 forms of the BCR\/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J. Exp. Med. 189, 1399\u20131412 (1999).","journal-title":"J. Exp. Med."},{"key":"BFnm0201228_CR32","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V96.3.925","volume":"96","author":"MC Heinrich","year":"2000","unstructured":"Heinrich, M.C. et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96, 925\u2013932 (2000).","journal-title":"Blood"},{"key":"BFnm0201228_CR33","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1182\/blood.V83.5.1179.1179","volume":"83","author":"A McGahon","year":"1994","unstructured":"McGahon, A. et al. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 83, 1179\u20131187 (1994).","journal-title":"Blood"},{"key":"BFnm0201228_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1172\/JCI9083","volume":"105","author":"BJ Druker","year":"2000","unstructured":"Druker, B.J. & Lydon, N.B. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Invest. 105, 3\u20137 (2000).","journal-title":"J. Clin. Invest."},{"key":"BFnm0201228_CR35","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/S0140-6736(00)02029-8","volume":"355","author":"JM Goldman","year":"2000","unstructured":"Goldman, J.M. Tyrosine-kinase inhibition in treatment of chronic myeloid leukaemia. Lancet 355, 1031\u20131032 (2000).","journal-title":"Lancet"},{"key":"BFnm0201228_CR36","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1093\/jnci\/92.1.6","volume":"92","author":"B Vastag","year":"2000","unstructured":"Vastag, B. Leukemia drug heralds molecularly targeted era. J. Natl. Cancer Inst. 92, 6\u20138 (2000).","journal-title":"J. Natl. Cancer Inst."},{"key":"BFnm0201228_CR37","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1182\/blood.V95.5.1758.005a41_1758_1766","volume":"95","author":"P le Coutre","year":"2000","unstructured":"le Coutre, P. et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 95, 1758\u20131766 (2000).","journal-title":"Blood"},{"key":"BFnm0201228_CR38","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1182\/blood.V95.11.3498","volume":"95","author":"E Weisberg","year":"2000","unstructured":"Weisberg, E. & Griffin, J.D. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR\/ABL-transformed hematopoietic cell lines. Blood 95, 3498\u20133505 (2000).","journal-title":"Blood"},{"key":"BFnm0201228_CR39","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","volume":"96","author":"FX Mahon","year":"2000","unstructured":"Mahon, F.X. et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96, 1070\u20131079 (2000).","journal-title":"Blood"},{"key":"BFnm0201228_CR40","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1093\/jnci\/92.20.1641","volume":"92","author":"C Gambacorti-Passerini","year":"2000","unstructured":"Gambacorti-Passerini, C. et al. Role of alpha1 Acid Glycoprotein in the In Vivo Resistance of Human BCR-ABL(+) Leukemic Cells to the Abl Inhibitor STI571. J. Natl. Cancer Inst. 92, 1641\u20131650 (2000).","journal-title":"J. Natl. Cancer Inst."},{"key":"BFnm0201228_CR41","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/bjc.1996.415","volume":"74","author":"ES Newlands","year":"1996","unstructured":"Newlands, E.S., Rustin, G.J. & Brampton, M.H. Phase I trial of elactocin. Br. J. Cancer 74, 648\u2013649 (1996).","journal-title":"Br. J. Cancer"},{"key":"BFnm0201228_CR42","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1128\/MCB.11.3.1553","volume":"11","author":"JR McWhirter","year":"1991","unstructured":"McWhirter, J.R. & Wang, J.Y. Activation of tyrosinase kinase and microfilament-binding functions of Abl by bcr sequences in bcr\/abl fusion proteins. Mol. Cell. Biol. 11, 1553\u20131565. (1991).","journal-title":"Mol. Cell. Biol."},{"key":"BFnm0201228_CR43","doi-asserted-by":"publisher","first-page":"5531","DOI":"10.1128\/MCB.15.10.5531","volume":"15","author":"D Cortez","year":"1995","unstructured":"Cortez, D., Kadlec, L. & Pendergast, A.M. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol. Cell. Biol. 15, 5531\u20135541 (1995).","journal-title":"Mol. Cell. Biol."},{"key":"BFnm0201228_CR44","doi-asserted-by":"publisher","first-page":"8392","DOI":"10.1073\/pnas.90.18.8392","volume":"90","author":"WS Pear","year":"1993","unstructured":"Pear, W.S., Nolan, G.P., Scott, M.L. & Baltimore, D. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA 90, 8392\u20138396 (1993).","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nm0201_228.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm0201_228","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm0201_228.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T23:32:00Z","timestamp":1684452720000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nm0201_228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,2]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2001,2]]}},"alternative-id":["BFnm0201228"],"URL":"https:\/\/doi.org\/10.1038\/84683","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,2]]}}}